Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by nodaytraderon Jan 02, 2024 3:41pm
70 Views
Post# 35807632

RE:RE:Today’s Trading

RE:RE:Today’s Trading

Vous avez raison de dire que les actions sont dcotes

 

La lettre d'intention de Seyltx signifie qu'un groupe d'investisseurs sophistiqus est prt investir entre 11 et 14 millions de dollars canadiens pour une part de 80 % dans une seule thrapie.

 

Mme au seuil de rentabilit, cela valorise lui seul les actions d'Algernon entre 0,73 et 0,91 dollars, mais elles se ngocient moins d'un dixime de ce montant.

 

Je ne comprends pas pourquoi les gens blment l’entreprise pour le cours de l’action. Le travail de l’entreprise est de crer de la valeur conomique et elle l’a clairement fait.

 

Le faible cours de l’action semble tre contrl par les traders.

 

"Dans les eaux peu profondes, un dragon est le jouet des crevettes"

 

You are right to say the shares are discounted

 

The Seyltx  LOI means that a group of sophisticated investors is willing to invest CAN$11-14million for an 80% share of a single therapy.

 

Even at break-even, this alone values Algernon shares at $0.73- $0.91 yet they trade at less than one-tenth of that.

 

I cannot understand why people blame the company for the share price. The company’s job is to create economic value and they have clearly done that.

 

The low share price appears to be controlled by traders.

 

“In shallow waters, a dragon is the plaything of shrimps”

<< Previous
Bullboard Posts
Next >>